Current collaborations include:
Polyganics is working together with Elana BV, a subsidiary of the BTI, on the development of products for managing cerebrospinal fluid (CSF) leakage after duratomy (incision of the tough, outer membrane of the brain and spinal cord).
BTI is a unique, independent non-profit organization that has the ultimate goal of improving the quality of life for people with cerebrovascular diseases. BTI is located in Utrecht and has close collaborations with the departments of neurosurgery at the University Medical Center Utrecht (NL), University Hospital Zurich (CH), Toronto University Health Network (CA) and Lenox Hill Hospital New York (USA). With BTI’s facilities, know-how and network, the organization is able to translate the results of research done in the laboratory to develop new technological products to treat patients.
Polyganics is providing a Research Grant to the Queen Elizabeth University Hospital, more in particular, the Birmingham Hand Centre which is carrying out a randomized controlled trial, the CONNECT study. The aim of the study, led by Principal Investigator Mr. Dominic Power is to investigate “tensionless repair” efficacy with NEUROLAC®. In total, more than 170 patients will be evaluated over 36 months.
University Hospitals Birmingham NHS Foundation Trust (UHB) is one of the highest performing NHS organizations in Europe with a proven international reputation for its quality of care, information technology, clinical education and training and research. The Trust is also a regional Neuroscience and Major Trauma Centre and is world-renowned for its trauma care. The Hand Unit at Queen Elizabeth Hospital Birmingham is one of the largest in the country. With the addition of the elective care provided at the Royal Orthopaedic Hospital (ROH), it provides a comprehensive service to treat all conditions of the adult hand.
Polyganics’ SHIELDS project focuses on the development of an innovative device with beneficial properties for Hepato-Pancreato-Biliary (HPB) surgery to reduce post-operative complications. The bioresorbable sealant patch controls both intra- and post-operative bleedings and prevents long-term surgery specific fluid leakage. This project is a collaborative development with the surgical department of the University Medical Center Hamburg-Eppendorf (UKE), which among other fields focuses on HPB surgery.
Since its foundation in 1889, the UKE has been one of the leading clinics in Europe. Based on the interconnection of medicine, research, and teaching, the UKE shares a common aim; improved patient health and well-being. The UKE is comprised of 14 centers and more than 80 interdisciplinary cooperating clinics, polyclinics, and institutes. Each year the UKE treats around 92,000 inpatients and 291,000 outpatients. SHIELDS is financially supported by VIA.
Polyganics collaborates with the Complex Tissue Regeneration (CTR) department of the MERLN Institute to investigate 3D printing technology for future personalized medical applications based on our proprietary polymers. The aim is to develop patient specific temporary scaffolds for guided and improved tissue regeneration. The addition of active substances that functionalize the 3D complex structures can further enhance patient recovery.
Research at MERLN is focused on developing novel and breakthrough technologies to advance the field of functional repair and regeneration of both tissues and organs. At CTR, advanced macro-, micro- and nano-biofabrication technologies are developed and combined with fundamental science towards the design of complex tissues and organs. The collaborative game-changing initiative is financially supported by VIA, a grant for innovative and high impact development.
To discuss co-development opportunities, please contact our Business Development department.